Clinical Trial Update: Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating anlotinib in combination with dose-reduced olaparib for platinum-sensitive recurrent ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Olaparib (Olaparib)

Snippet

Sponsor: Xiaoxiang Chen | Conditions: Ovarian Cancer, Ovarian and Fallopian Tube Cysts and Neoplasms | Phase 2 | Status: UNKNOWN